Business Context and Reporting Period
ImmuCell Corporation (ICCC), a Delaware corporation headquartered in Portland, Maine, filed this Form 8-K on August 20, 2025. The report details a material definitive agreement entered into on the same date regarding the company's credit facilities.
Key Financial Metrics
This filing does not contain comprehensive financial statements, revenue, profit, or cash flow data. The only specific financial metric disclosed is the extension of a $1 million line of credit with Maine Community Bank (MCB). Interest on borrowings is variable, tied to the National Prime Rate per annum.
Material Changes
- Credit Facility Extension: The maturity date of the existing $1 million line of credit with MCB has been extended from its previous term to September 11, 2026.
- Agreement Type: The change was effected through an "Allonge to and Amendment of Line of Credit."
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard obligations of the amended credit agreement. The document focuses solely on the administrative extension of the debt instrument.
Investor Verification Checklist
- Verify the current utilization status of the $1 million line of credit to assess immediate liquidity needs.
- Confirm the current National Prime Rate to calculate the effective interest cost of the facility.
- Review the full text of Exhibit 10.1 (Allonge to and Amendment of Line of Credit) for any new covenants or conditions attached to the extension.
- Check subsequent filings for any drawdowns on this extended facility.